Bicara therapeutics reports fourth quarter and full year 2024 financial results and provides business update

Dosing commenced in fortifi-hn01, a pivotal phase 2/3 trial of ficerafusp alfa in 1l r/m hnscc updated data from ongoing phase 1/1b trial in 1l r/m hnscc to be presented at 2025 asco annual meeting strong financial position with approximately $490 million in cash and cash equivalents expected to fund operations into the first half of 2029 boston, march 27, 2025 (globe newswire) -- bicara therapeutics inc. (nasdaq: bcax), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the fourth quarter and full year ended december 31, 2024 and provided a business update. “2024 was a remarkable year for bicara, marked by our successful transition to a public company, the advancement of our lead asset, ficerafusp alfa, and the addition of key leaders to our executive team and board of directors.
BCAX Ratings Summary
BCAX Quant Ranking